HEMEX AG

Their core work

HEMEX AG is a Swiss medical technology SME based in Liestal, near the Basel medtech cluster, specializing in precision medical devices and surgical systems. Their most substantial EU project involvement was in SAFE-CAB, where they contributed to developing a laser-assisted surgical system designed to make coronary artery bypass surgery minimally invasive — a high-stakes, high-precision application requiring deep knowledge of surgical implants and cardiac device engineering. More recently, they appeared as a third party in Embryospin, a project applying nuclear magnetic resonance to quantify embryo quality for IVF — suggesting they possess underlying measurement or instrumentation expertise that transfers across medical domains. Their profile points to a small but technically specialized company bridging precision surgical hardware and quantitative biomedical assessment.

What they specialise in

How they've shifted over time

HEMEX's early H2020 engagement (2019) was firmly rooted in cardiac surgery — surgical implants, laser-assisted bypass systems, and clinical trials for a high-risk cardiovascular device. By 2021, their focus shifted toward reproductive medicine and NMR-based embryo assessment, a domain with very different clinical and commercial dynamics. This pivot — from high-stakes cardiac hardware to quantitative IVF diagnostics — may reflect either a deliberate expansion of their medtech portfolio or the application of shared underlying technology (precision instrumentation or measurement systems) to a new clinical market.

HEMEX appears to be moving from single-domain cardiac device work toward cross-domain precision measurement in reproductive medicine, which may indicate interest in broader medtech instrumentation roles in future consortia.

How they like to work

HEMEX has never led an H2020 project as coordinator — they enter consortia as a specialist participant or third party, contributing specific technical capabilities rather than orchestrating the broader effort. Their consortium footprint is small (6 partners across 3 countries), which suggests targeted, project-specific collaboration rather than broad network building. For prospective partners, this profile indicates a company that contributes deep technical expertise in a defined scope, rather than one seeking to manage multi-partner programs.

HEMEX has worked with 6 unique consortium partners across 3 countries, a modest network consistent with a focused SME that joins selected, high-fit projects. No geographic concentration pattern is identifiable from the data, though their Swiss base aligns them naturally with the Basel–Rhine medtech corridor.

What sets them apart

HEMEX is unusual among small medtech SMEs in having demonstrable experience in two quite different clinical domains — cardiac bypass surgery devices and IVF embryo diagnostics — within the span of just two projects. This cross-domain range, combined with their Swiss location in one of Europe's most concentrated medtech environments, gives them credibility as a specialist partner for consortia that need precision medical device or biomedical measurement expertise. A consortium builder looking for a technically grounded Swiss SME with clinical trial experience and NMR instrumentation background would find few equivalents at this scale.

Highlights from their portfolio

• SAFE-CAB
  Their largest and most substantive EU engagement — EUR 903,875 in EC funding as a direct participant — targeting a high-impact problem in cardiac surgery with a laser-assisted bypass system that reached clinical trial stage.
• Embryospin
  Though HEMEX entered as a third party with no direct EC funding, this project signals a strategic expansion into reproductive medicine using NMR — a technically sophisticated, commercially growing field.